Prior Approval Supplement (PAS): When Required and How to File

Prior Approval Supplement (PAS): When Required and How to File

Key Takeaways

What Is a Prior Approval Supplement?

A Prior Approval Supplement (PAS) is the most rigorous reporting mechanism for post-approval changes to an approved NDA or ANDA. Under 21 CFR 314.70(b), a PAS is required when a proposed change has a "substantial potential to have an adverse effect on the identity, strength, quality, purity, or potency of the drug product as these factors may relate to the safety or effectiveness of the drug product."

The critical distinction between a PAS and CBE supplements (CBE-0, CBE-30) is that the applicant cannot implement the change or distribute product made with the change until FDA approves the PAS. This is a hard requirement, not a suggestion. Distribution of product made under an unapproved PAS change constitutes distribution of an unapproved new drug, which violates Section 301 of the FD&C Act.

When Is a PAS Required?

Changes Explicitly Requiring PAS Under 21 CFR 314.70(b)

The regulation provides a non-exhaustive list of changes that require a PAS. The following are specified in 21 CFR 314.70(b)(2):

Efficacy Supplements:

• Addition of a new indication or claim
• Addition of a new patient population (e.g., pediatric indication)
• Change in dosing regimen based on new clinical data
• Modification of effectiveness claims

CMC (Chemistry, Manufacturing, and Controls) Changes:

• Changes in the qualitative or quantitative formulation of the drug product (except those within SUPAC-specified ranges for CBE-30)
• Changes in the synthesis or manufacture of the drug substance that may affect impurity profile
• Relaxation of specification limits or deletion of a test from the specification
• Changes in the method of drug product sterilization
• Changes in the manufacturing process, equipment, or controls that may affect product quality beyond what is supported by existing data
• Changes in the container closure system that affect drug product stability, purity, or quality
• Establishment of a new manufacturing site involving process changes

Labeling Changes:

• Efficacy supplement labeling (new indications)
• Certain promotional labeling changes

SUPAC-Defined PAS Changes (Level 3)

The SUPAC guidances define Level 3 changes as requiring PAS filing. Examples from SUPAC-IR:

Changes Commonly Misclassified

Several change types are frequently filed under the wrong reporting category. These deserve specific attention:

PAS Content and Format Requirements

eCTD Structure

A PAS submission is an eCTD sequence within the existing application lifecycle. It follows the standard ICH eCTD structure but includes only the modules and sections relevant to the change.

Submission metadata:

• Submission type: Supplement
• Submission sub-type: Prior Approval
• Sequence number: Next sequential number in the application lifecycle
• Application number: Same NDA/ANDA number

Module 1: Administrative Information

Module 2: Summaries

Module 3: Quality (CMC Changes)

For CMC PAS submissions, include only the sections that are affected by the change. Common sections:

Module 5: Clinical Study Reports (Efficacy Supplements)

Efficacy supplements must include the clinical data supporting the new indication. This follows the same format as the original NDA's Module 5, including:

• Clinical study reports per ICH E3
• Integrated summaries of safety and efficacy (ISS/ISE)
• Case report forms and datasets (if requested)

PDUFA Review Timelines

PAS supplements are subject to Prescription Drug User Fee Act (PDUFA) review goals. The applicable timeline depends on the supplement classification:

Standard vs. Priority Review

Supplement Classification and Timing

Not all PAS supplements have the same PDUFA timeline. FDA classifies supplements internally, which affects review allocation:

User Fee Requirements

PAS supplements are subject to PDUFA user fees unless an exemption applies. As of FY2026, supplement user fees are published annually by FDA. Small businesses and certain supplement types may qualify for fee waivers or reductions.

The PAS Review Process

Stages of Review

Filing Review (Days 0-60)

During the first 60 days, FDA conducts a filing review to determine whether the supplement is sufficiently complete to permit substantive review. FDA may:

• File the supplement: Proceed to substantive review. FDA issues a filing letter.
• Refuse to file (RTF): Determine the submission is too incomplete to review. This resets the clock entirely — the applicant must address deficiencies and resubmit.

Common reasons for RTF of PAS supplements:

Substantive Review (Days 60-300)

FDA reviewers evaluate the scientific and regulatory merits of the supplement. During this phase:

• Information Requests (IRs): FDA may issue IRs requesting clarification or additional data. The applicant has a defined response period. Some IRs stop the review clock; others do not.
• Discipline Review Letters (DRLs): Individual review disciplines (chemistry, microbiology, clinical pharmacology) may issue questions.
• Advisory Committee review: Rare for CMC supplements, but possible for efficacy supplements with significant safety questions.

Action (Day 300 or PDUFA Goal Date)

FDA issues one of the following actions:

Common PAS Deficiencies

Based on publicly available FDA communications and industry experience, the following are frequent deficiency categories in PAS submissions:

CMC Deficiencies

Efficacy Supplement Deficiencies

eCTD Sequence Numbering for PAS

How Sequences Work

Each eCTD submission to an application gets a unique, sequential number. The PAS supplement receives the next available sequence number, regardless of what the previous sequence was (it could have been an annual report, a CBE-30, or an amendment to a previous supplement).

Example sequence history:

Amendments to PAS

If FDA issues an Information Request during PAS review, the applicant responds by submitting an amendment to the supplement. This amendment is a new eCTD sequence that references the original PAS sequence.

Amendment content:

• Cover letter referencing the PAS sequence number and the IR date
• Only the sections being updated or added in response to the IR
• Use lifecycle operations: "replace" for updated documents, "new" for additional documents

Strategies for Managing PAS Timeline

Pre-Submission Planning

1. File a Pre-Submission Meeting Request (Type C meeting). For complex changes, request a meeting with FDA to discuss the change, proposed supporting data, and regulatory strategy. FDA's Guidance for Industry on Formal Meetings Between FDA and Sponsors or Applicants of PDUFA Products describes procedures for Type A, B, and C meetings, and allows for written-only responses if a face-to-face meeting is not warranted.
2. Conduct a gap analysis. Before filing, compare the proposed PAS content against FDA expectations for the specific change type. Use SUPAC guidance, FDA reviewer aids, and relevant FDA guidance documents.
3. Prepare validation and stability studies early. The most common timeline bottleneck is waiting for stability data. Initiate stability studies on post-change product as soon as the change is finalized in development.

During Review

1. Respond to IRs promptly and completely. FDA tracks response times. Late or incomplete responses can delay the PDUFA action date or result in a CRL.
2. Request a mid-cycle meeting if needed. If significant questions arise during review, request an informal meeting with the review team.
3. Track the PDUFA date. The PDUFA goal date is the date by which FDA commits to completing its review. It is not the date of approval — it is the date by which FDA will take action (approval, CRL, or extension).

If a CRL Is Issued

1. Analyze the CRL carefully. Identify all deficiencies and categorize them as resolvable (data available or obtainable) vs. fundamental (requiring new studies).
2. Respond with a Class 1 or Class 2 resubmission. A Class 1 resubmission (minor changes, no new clinical data) has a 2-month review goal. A Class 2 resubmission (major changes, new data) has a 6-month review goal.
3. Consider requesting a post-CRL meeting. If the deficiencies are unclear or complex, request a Type A meeting to discuss FDA's expectations before resubmitting.

PAS for Biologics: 21 CFR 601.12(b)

Biologics License Applications (BLAs) follow 21 CFR 601.12 instead of 314.70. The PAS framework is similar, but biologics have additional requirements:

• Manufacturing process changes for biologics are generally held to a higher standard because "the process is the product"
• Comparability assessments for biologics must follow ICH Q5E, which may require functional assays, bioassays, and physicochemical characterization
• Potency assays specific to the biological product are typically required
• Process changes that could affect post-translational modifications (glycosylation, charge variants, aggregation) almost always require PAS

Key Regulatory References

References